extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
771853f978
commit
0d6bd43fd0
4 changed files with 32 additions and 5 deletions
|
|
@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl
|
|||
|
||||
International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
|
||||
|
||||
If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -95,6 +95,12 @@ Aon data shows the 80%+ adherent cohort captures dramatically stronger cost redu
|
|||
|
||||
GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19*
|
||||
|
||||
Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -10,16 +10,17 @@
|
|||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"fixed": 3,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-18",
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d"
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:set_created:2026-03-19",
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-60-percent-better-weight-maintenance-than-medication-alone-after-discontinuation.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
"date": "2026-03-19"
|
||||
}
|
||||
|
|
@ -7,13 +7,17 @@ date: 2026-03-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: review
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-19
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -88,3 +92,13 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison
|
|||
- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions
|
||||
- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication)
|
||||
- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source
|
||||
|
||||
|
||||
## Key Facts
|
||||
- WHO December 2025 guidelines specifically recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits'
|
||||
- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass
|
||||
- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced
|
||||
- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions
|
||||
- At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg
|
||||
- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication)
|
||||
- ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet
|
||||
|
|
|
|||
Loading…
Reference in a new issue